Copyright
©The Author(s) 2022.
World J Hepatol. Jul 27, 2022; 14(7): 1307-1318
Published online Jul 27, 2022. doi: 10.4254/wjh.v14.i7.1307
Published online Jul 27, 2022. doi: 10.4254/wjh.v14.i7.1307
Diseases | Types of molecules | Markers | Refs. |
HCC | Protein | Aminopeptidase N, Galectin-3-binding protein, SMAD, ANGPT2, 14-3-3 ζ, β-catenin, P120-catenin, EPCAM | [15–21] |
RNA | miR-21, miR-21, -96, miR-122, miR-18a, -221, -222, -224, miR-10b-5p, -215-5p, miR-101, -106b, 12, -195, miR-519d, -595, -939, miR-19b,-92, miR-125, miR-9-3, miR-122, 148a, -1246, miR-122, miR-93, miR 144-3p, -21-5p, miR210, miR-638, miR-665, miR-774, miR-1262, miR-320d, miR-23a/b, miR-45-1a, miR-224, miR-21, -10b, miR-122, -125b, -145, -192, -194, 29a, 17-5p, -106a, miR-26a, -29c, -21, lncRNA Jpx, lncRNA FAL1, lncRNA-RP11-513I15.6, mRNA RAB11A, miR-1262, lncRNA HEIH, lncRNA LINC00161, lnc RNA HULC, AFP mRNA | [22–50] | |
HBV | miRNA | miR-21-5p | [33] |
HCV | RNA | HCV-RNA, miR-122-5p, -222-3p, -146-5p, -150-5p, -30c-5p, -378a-3p, -20a-5p, | [51–53] |
NAFLD/NASH | Protein | ITGβ1, CD68 | [54,55] |
RNA | miR-192-5p | [56] | |
Lipid | ceramides and sphingosin 1-phosphate | [57] | |
ALD | Protein | ASGR2 and CYP2E1, CD163, 206, ASGPR, CD40L, CK18, Glutathione synthetase | [55,58–62] |
RNA | miR-122, -155, miR-Let-7f, 29a, -340, miR-122, let7f, -21, -29a, -146a, miR-192-5p, miR-192, -30a | [56,63–66] | |
Lipid | Sphingosin 1-phosphate | [67] | |
Cirrhosis | Protein | CD163, 206, PDGFRβ, urinary maltase and glucoamylase (for AKI during cirrhosis) | [59,68–70] |
RNA | miR-19a, -19b, -92, 17a, -20a | [27] | |
ALI | Protein | Apolipoprotein A-1, Argininosuccinate synthase-1 | [62] |
RNA | Gnb21 mRNA, | [71] |
Pathophysiology | Types of molecules | Markers | Refs. |
NASH inflammation and fibrosis | miRNA | miR-122, -192 | [75] |
NASH fibrosis | miRNA | miR-122 | [76] |
ALD outcome | protein | ASGR2 and CYP2E1 | [58] |
HBV fibrosis | miRNA | miR-150, -192, -200b, -91a | [77] |
HCV treatment response | miRNA | miR-122, -199a, miR-122, miR-122-5p, -222-3p, -146-5p, -150-5p, -30c-5p, -378a-3p, -20a-5p | [53,78,79] |
HCV fibrosis | protein | CD81 | [80] |
miRNA | Let-7s, miR-122, -150, -192, 200b, 92a, miR-19a | [77,81] | |
HCC recurrence | protein | SMAD3, CASC9 | [16,82] |
RNA | miR-718, miR-125, miR-21, miR-103, miR1247-3p, miR-92b, miR-21 and lncRNA-ATB, miR-21, -10b, miR-215-5p, miR-155, mRNA RAB11A, miR-211-3p, -6826-3p, -1236-3p, 4448 | [25,26,36,42,83–90] | |
HCC survival | RNA | miR-125, miR-21, miR-103, miR-22a-3p, miR-335, miR-25-5p, miR-320a-PBX3, miR-718, miR-210, miR-122, miR-93, miR-21, -96, -122, miR-1247-3p, miR-638, miR-665, miR-21 and lncRNA-ATB, miR-30d, -140, miR-106a, miR-224, miR-320d, long non-coding RNA (ENSG00000258332.1 and LINC00635), hnRNPH1, circPTGR1, circRNA-100, -338, circ DB | [18,23,31,32,34,36,38,41,43,82–86,88,91–99] |
- Citation: Tsuchiya A, Natsui K, Ishii Y, Koseki Y, Takeda N, Tomiyoshi K, Yamazaki F, Yoshida Y, Terai S. Small extracellular vesicles and liver diseases: From diagnosis to therapy. World J Hepatol 2022; 14(7): 1307-1318
- URL: https://www.wjgnet.com/1948-5182/full/v14/i7/1307.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i7.1307